ZAVEGEPANT HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pfizer	ZAVZPRET	zavegepant hydrochloride	SPRAY, METERED;NASAL	216386	NDA	Pfizer Laboratories Div Pfizer Inc	0069-3500-02	6 BLISTER PACK in 1 CARTON (0069-3500-02) / 1 VIAL, SINGLE-DOSE in 1 BLISTER PACK (0069-3500-01) / .1 mL in 1 VIAL, SINGLE-DOSE	2023-06-01
Pfizer	ZAVZPRET	zavegepant hydrochloride	SPRAY, METERED;NASAL	216386	NDA	U.S. Pharmaceuticals	63539-135-02	1 BLISTER PACK in 1 CARTON (63539-135-02) / 1 VIAL, SINGLE-DOSE in 1 BLISTER PACK (63539-135-01) / .1 mL in 1 VIAL, SINGLE-DOSE	2023-06-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

Zavegepant hydrochloride is an investigational drug primarily developed for the acute treatment of migraines. It belongs to the class of calcitonin gene-related peptide (CGRP) receptor antagonists, offering promising therapeutic options for migraine sufferers. As a relatively novel compound in the pharmaceutical landscape, sourcing zavegepant hydrochloride involves navigating a complex network of chemical suppliers, contract manufacturing organizations (CMOs), and pharmaceutical material providers. This article provides a comprehensive analysis of current suppliers, market dynamics, and strategic considerations pertinent to stakeholders interested in zavegepant hydrochloride.

Overview of Zavegepant Hydrochloride

Chemical Profile and Development Status:
Zavegepant hydrochloride (INN, International Nonproprietary Name) is a small-molecule CGRP receptor antagonist designed to mitigate migraine attacks effectively. Its development has been championed by pharmaceutical companies such as Pfizer, with clinical trials demonstrating favorable efficacy and safety profiles. As an investigational drug, it remains under regulatory review, with manufacturing and supply chains still evolving to meet commercial demand upon approval.

Market Position:
Pending regulatory approval, zavegepant is expected to occupy a significant niche within migraine therapeutics, competing with existing CGRP antagonists such as ubrogepant and rimegepant. Its unique delivery forms and formulation stability are critical factors influencing manufacturing and supply considerations.

Current Suppliers of Zavegepant Hydrochloride

Given its investigational status, direct suppliers of zavegepant hydrochloride are limited, primarily comprising specialized chemical manufacturers and contract organizations involved in early-phase API (Active Pharmaceutical Ingredient) production.

1. Contract Manufacturing Organizations (CMOs) and API Manufacturers

Multiple CMOs capable of synthesizing complex small-molecule APIs, including zavegepant hydrochloride, are potential suppliers. These organizations typically operate under confidential agreements, providing large-scale synthesis, purification, and quality assurance services.

Lonza: A leading CMO with extensive expertise in peptide and small-molecule APIs, Lonza has been active in developing manufacturing processes aligned with regulatory standards. Although not publicly confirmed for zavegepant production, their capabilities place them among potential suppliers in this domain.
Catalent: As a global provider of drug development and manufacturing solutions, Catalent possesses facilities capable of producing complex APIs. Their experience with CGRP antagonists and migraine therapeutics enhances their suitability as potential supply partners.
WuXi AppTec: With a broad portfolio supporting early-phase clinical supplies, WuXi offers custom synthesis and process development services for investigational drugs, including candidates like zavegepant hydrochloride.
Thermo Fisher Scientific: Engaged in API synthesis for various therapeutic classes, Thermo Fisher's scale and experience make it a candidate for zavegepant manufacturing, especially at pilot and commercial scales.

2. Chemical Intermediates Suppliers

The synthesis of zavegepant hydrochloride requires specialized intermediates, such as specific heterocyclic compounds and hydrochloride salts, supplied by chemical intermediates manufacturers.

Sigma-Aldrich / MilliporeSigma: As a major integrator of chemical reagents, they provide high-purity raw materials that can be utilized in API synthesis, including intermediates relevant to zavegepant's chemical structure.
Alfa Aesar: Supplies specialty chemicals and intermediates, which could be crucial in the multi-step synthesis pathways.
Tokyo Chemical Industry (TCI): Provides a range of heterocyclic compounds and chemical intermediates suitable for pharmaceutical synthesis.

3. Specialty Chemical Suppliers

Certain niche chemical suppliers might offer precursor chemicals or intermediates used in zavegepant hydrochloride synthesis. These suppliers focus on high-purity reagents required for GMP-compliant manufacturing.

VWR Chemicals: Offers a variety of chemical reagents at research and production scales.
TCI America / Europe: Supplies custom and catalog chemicals, essential for drug synthesis processes.

Emerging and Future Supply Chain Dynamics

The current supply landscape for zavegepant hydrochloride is nascent, primarily driven by ongoing clinical development. With the potential market entry approaching, new suppliers are expected to emerge, especially as manufacturing processes mature and scale requirements increase.

Strategic Partnerships: Pharmaceutical developers may establish exclusive supply agreements with specific CMOs or chemical manufacturers to ensure supply stability, quality, and regulatory compliance.
Regional Supply Considerations: Suppliers’ global distribution networks influence drug accessibility and manufacturing costs, with Asia-Pacific (notably China and India) serving as significant hubs for chemical manufacturing of APIs, including potential source zones for zavegepant intermediates.
Regulatory Implications: Suppliers must adhere to Good Manufacturing Practice (GMP) standards mandated by agencies like the FDA and EMA. Only suppliers with validated GMP facilities will be eligible for supplying commercial quantities of zavegepant hydrochloride.

Challenges in Supply Chain Management

Complex Synthesis Processes: The intricate multi-step synthesis routes for zavegepant require highly specialized chemical expertise and tight process controls, limiting the pool of qualified suppliers.
Regulatory Validation: Suppliers need to establish batch-to-batch consistency, impurity profiles, and purity standards aligned with regulatory expectations.
Supply Chain Security: Ensuring uninterrupted supply amid geopolitical, logistical, and pandemic-related disruptions remains critical.

Conclusion

While direct, widespread suppliers for zavegepant hydrochloride are currently limited due to its investigational status, the landscape is evolving. Leading CMOs such as WuXi AppTec, Catalent, and Thermo Fisher Scientific are poised to become primary manufacturing partners upon regulatory approval. Chemical intermediates and precursor chemicals are accessible from major suppliers like Sigma-Aldrich and TCI, supporting the complex synthesis pathways involved.

For stakeholders aiming to secure reliable supply chains, forging strategic partnerships with GMP-compliant manufacturers and maintaining close engagement with regulatory authorities are essential. As the drug advances through clinical stages to eventual commercialization, the supplier network is expected to expand, ensuring broad access and sustainable manufacturing capacity.

Key Takeaways

The supply chain for zavegepant hydrochloride is currently characterized by a few specialized CMOs and chemical intermediates providers, reflecting its investigational status.
Strategic alliances with GMP-certified manufacturers are vital to ensure consistent, regulatory-compliant supply upon drug approval.
The complexity of synthesis pathways necessitates high levels of chemical expertise, limiting the pool of qualified suppliers.
Regional manufacturing hubs in Asia-Pacific could play a pivotal role in large-scale production and supply chain resilience.
Continuous monitoring of regulatory developments and supplier qualification processes is critical for stakeholders planning long-term investment or procurement strategies.

Frequently Asked Questions (FAQs)

1. Who are the main suppliers for zavegepant hydrochloride?
Currently, specialized CMOs like WuXi AppTec, Catalent, and Thermo Fisher Scientific are potential suppliers, especially as manufacturing processes mature. Direct information on commercial-scale suppliers remains limited due to its investigational status.

2. Can I procure zavegepant hydrochloride from chemical intermediates suppliers?
Yes, intermediates such as heterocyclic compounds are accessible from chemical suppliers like Sigma-Aldrich and TCI. However, GMP-grade intermediates required for final API production necessitate collaboration with licensed manufacturers.

3. What are the key challenges in sourcing zavegepant hydrochloride?
Challenges include complex synthesis routes, stringent regulatory compliance, limited supplier pool, and the need for GMP certification to ensure quality and purity standards.

4. How does regulatory status impact supply chain options?
Since zavegepant is still under clinical development, supply options are primarily limited to research-grade materials. Commercial manufacturing will require GMP-certified suppliers, expanding options significantly upon drug approval.

5. Are there regional supply considerations to be aware of?
Yes, Asia-Pacific regions, especially China and India, serve as significant hubs for chemical manufacturing, which can influence costs, lead times, and supply security depending on regional trade policies and logistics.

Sources
[1] Pfizer Inc. Clinical trial data and drug development pipeline.
[2] Pharmea. "CGRP Antagonists and Migraine Therapy."
[3] industry reports on pharmaceutical chemical manufacturing.
[4] GMP guidelines from the FDA and EMA.

Suppliers and packagers for generic pharmaceutical drug: ZAVEGEPANT HYDROCHLORIDE